KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Patrick Malone and Mack Healy discuss the biopharma R&D software juggernaut, Schrödinger. We dive into:
Schrödinger's biophysics-based drug discovery platform, and the distinction from machine learning approaches
A dissection of Schrödinger's software business, as well as co-development partnerships and internal therapeutic programs
The story of Schrödinger collaboration with Nimbus on a TYK2 program, resulting in a $4B+ acquisition by Takeda
and more
Links to the full episode and highlights from the discussion:
If you enjoyed this episode, check out past episodes on Royalty Pharma, Recursion, Editas, AbCellera, and more.
No posts
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.